---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-008863"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2025-02-04T23:59:59+00:00"
generated_at: "2026-05-27T03:42:09.434020+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Merck Q4 2024 sales $15.6B (+7% YoY); GAAP EPS $1.48, Non-GAAP $1.72; FY2025 guidance issued

## Summary
- Full-year 2024 worldwide sales $64.2B (+7% YoY; +10% ex-FX).
- Q4 GAAP EPS $1.48; Non-GAAP EPS $1.72 (includes $0.23 charge for licensing).
- KEYTRUDA full-year sales $29.5B (+18% YoY; +22% ex-FX).
- WINREVAIR full-year sales $419M; GARDASIL declined 3% to $8.6B on lower China demand.
- FY2025 guidance: sales $64.1-65.6B; Non-GAAP EPS $8.88-9.03 (incl. ~$0.09 LaNova charge).

## SEC filing metadata
- accession: 0001104659-25-008863
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2025-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465925008863/0001104659-25-008863-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465925008863/tm255059d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-008863
- JSON: https://secwatch.observer/filing/0001104659-25-008863.json
- Plain text: https://secwatch.observer/filing/0001104659-25-008863.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.